JNK inhibitor slows lung function decline in idiopathic pulmonary fibrosis
Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.“This was supported by improvements in circulating biomarkers of fibrosis and a reduction in respiratory [adverse events] in the CC-90001 arms,”